Date: 2014-01-09
Type of information: R&D agreement
Compound: RNA targeted medicines using Santaris Pharma\'s proprietary Locked Nucleic Acid (LNA) Drug Platform.
Company: Santaris Pharma (Denmark) Roche (Switzerland)
Therapeutic area: undisclosed
Type agreement: R&D
licensing
Action mechanism: The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combines the company\'s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver LNA-based drug candidates against both mRNA and microRNA, thus enabling scientists to develop drug candidates against diseases that are difficult, or impossible, to target with contemporary drug platforms such as antibodies and small molecules. The LNA Drug Platform overcomes the limitations of earlier antisense and siRNA technologies through a unique combination of small size and very high affinity that allows this new class of drugs candidates to potently and specifically inhibit RNA targets in many different tissues without the need for complex delivery vehicles. LNA is also sometimes referred to as BNA (Bicyclic or Bridged Nucleic Acid).
Disease: undisclosed
Details: * On January 9, 2014, Santaris Pharma, a privately held biopharmaceutical company, has announced that they have signed a worldwide strategic alliance with Roche to discover and develop novel RNA targeted medicines using Santaris Pharma\'s proprietary Locked Nucleic Acid (LNA) Drug Platform.
Under the terms of the agreement, Santaris Pharma and Roche will collaborate on the discovery of LNA drugs against a multitude of targets across several disease areas. Roche will be responsible for the subsequent development and commercialization of products arising from the alliance. Santaris Pharma will receive an upfront payment of $10 million in cash, up to $138M in potential pre-clinical, clinical, regulatory and sales milestones per product, and funding of ongoing discovery and research activities. In addition, Santaris Pharma will be eligible to receive royalties on the worldwide sales of all medicines arising from the alliance.
Financial terms:
Latest news:
